Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 90.6 mg (equivalent: ziprasidone, qty 80 mg) - capsule, hard - excipient ingredients: magnesium stearate; titanium dioxide; gelatin; pregelatinised maize starch; lactose monohydrate; indigo carmine; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for: (i) the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; and (ii) as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 67.95 mg (equivalent: ziprasidone, qty 60 mg) - capsule, hard - excipient ingredients: pregelatinised maize starch; gelatin; lactose monohydrate; titanium dioxide; magnesium stearate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for: (i) the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; and (ii) as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 45.3 mg (equivalent: ziprasidone, qty 40 mg) - capsule, hard - excipient ingredients: magnesium stearate; indigo carmine; titanium dioxide; lactose monohydrate; pregelatinised maize starch; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for: (i) the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; and (ii) as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 22.65 mg (equivalent: ziprasidone, qty 20 mg) - capsule, hard - excipient ingredients: titanium dioxide; pregelatinised maize starch; indigo carmine; gelatin; lactose monohydrate; magnesium stearate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for: (i) the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; and (ii) as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone mesilate, quantity: 27.29 mg (equivalent: ziprasidone, qty 20 mg) - injection, powder for - excipient ingredients: sulfobutyl betadex sodium - acute control and short-term management of agitation and disturbed behaviours in patients with schizophrenia and related psychoses when oral therapy is not appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 90.6 mg - capsule, hard - excipient ingredients: titanium dioxide; pregelatinised maize starch; lactose monohydrate; gelatin; indigo carmine; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ziprasidone hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ziprasidone mesilate -

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - ziprasidone hydrochloride monohydrate 45.3mg equivalent to 40 mg ziprasidone; ziprasidone hydrochloride monohydrate 67.95mg equivalent to 60 mg ziprasidone; ziprasidone hydrochloride monohydrate 90.6mg equivalent to 80 mg ziprasidone - capsule - active: ziprasidone hydrochloride monohydrate 45.3mg equivalent to 40 mg ziprasidone excipient: gelatin lactose monohydrate magnesium stearate pregelatinised maize starch active: ziprasidone hydrochloride monohydrate 67.95mg equivalent to 60 mg ziprasidone excipient: gelatin lactose monohydrate magnesium stearate pregelatinised maize starch active: ziprasidone hydrochloride monohydrate 90.6mg equivalent to 80 mg ziprasidone excipient: gelatin lactose monohydrate magnesium stearate pregelatinised maize starch - ziprasidone is also indicated as a monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar 1 disorder.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ziprasidone hydrochloride monohydrate 113.25mg equivalent to 100 mg ziprasidone - capsule - 100 mg - active: ziprasidone hydrochloride monohydrate 113.25mg equivalent to 100 mg ziprasidone excipient: lactose monohydrate magnesium stearate pregelatinised maize starch - ziprasidone is indicated for the treatment of acute schizophrenia, and maintenance or continuation therapy.